Characterization of Predictors of Response or Resistance to ICIs in NSCLC
PD-L1 expression density and cytotoxic T cells were identified as potential biomarkers for outcomes with ICIs in patients with NSCLC.
PD-L1 expression density and cytotoxic T cells were identified as potential biomarkers for outcomes with ICIs in patients with NSCLC.
The addition of apatinib to gefitinib prolonged PFS compared with gefitinib among treatment-naive patients with EGFR-mutated NSCLC.
The use of modern postoperative conformal radiotherapy did not improve DFS and was associated with toxicities among patients with stage IIIAN2 NSCLC.
NGS of longitudinal samples from patients with advanced NSCLC receiving ICIs identified changes associated with hyperprogression and early death.
Results from a phase 1 trial suggest a KRASG12C inhibitor has a favorable safety profile and antitumor activity in advanced NSCLC.
An analysis of from the Flatiron Health Network found that some patients with NSCLC with a KRASG12C mutation do not receive systemic therapy.
Several gene signatures were associated with outcomes among patients with advanced clear cell RCC, but not non-clear cell RCC.
Gene signatures were identified as potential predictive biomarkers for outcomes with nivolumab among patients with advanced ccRCC in an analysis of the NIVOREN GETUG-AFU 26 trial.
Circulating tumor DNA analysis of genomic alterations was concordant with tissue genomic analysis in a cohort of patients with advanced RCC.
Atezolizumab plus cabozantinib was tolerable and demonstrated antitumor activity in patients with treatment-naïve, advanced ccRCC, according to a phase 1b study.